<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02326051</url>
  </required_header>
  <id_info>
    <org_study_id>MIE2</org_study_id>
    <nct_id>NCT02326051</nct_id>
  </id_info>
  <brief_title>Timing of Initiation of LMWH Administration in Pregnant Women With APS</brief_title>
  <official_title>Timing of Initiation of Low Molecular Weight Heparin Administration in Pregnant Women With Antiphospholipid Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mohamed Sayed Abdelhafez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the effect of altering the timing of initiation of low molecular weight heparin
      (LMWH) administration on the pregnancy outcomes in women with antiphospholipid syndrome (APS)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women will be randomly divided into two groups; one will start Enoxaparin therapy once
      positive pregnancy test is established and the other will start Enoxaparin therapy after
      sonographic confirmation of fetal cardiac pulsation. In all women, Enoxaparin will be given
      in a dose of 40 mg/day subcutaneously and the therapy will continue until termination of
      pregnancy
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>After 12 weeks gestational age</time_frame>
    <description>Number of pregnancies that progressed beyond the critical first trimester (12 weeks gestational age) per number of pregnant women</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fetal loss</measure>
    <time_frame>From 20 weeks to 42 weeks gestational age</time_frame>
    <description>Unexplained fetal death of morphologically normal fetus after the first trimester</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preterm delivery</measure>
    <time_frame>From 20 weeks to 34 weeks gestational age</time_frame>
    <description>Delivery of morphologically normal fetus before 34 weeks of gestation due to severe preeclampsia or placental insufficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intrauterine growth restriction (IUGR)</measure>
    <time_frame>At birth</time_frame>
    <description>Birth weight less than the 10th percentile for gestational age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Congenital fetal malformations</measure>
    <time_frame>At birth</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Hemorrhagic complications</measure>
    <time_frame>After 12 weeks gestational age up to birth</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Thromboembolic complications</measure>
    <time_frame>After 12 weeks gestational age up to birth</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Recurrent Miscarriage</condition>
  <condition>Antiphospholipid Syndrome</condition>
  <arm_group>
    <arm_group_label>Early Enoxaparin initiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women will start Enoxaparin therapy once positive pregnancy test is established</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Later Enoxaparin initiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women will start Enoxaparin therapy after sonographic confirmation of fetal cardiac pulsation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>Women will start Enoxaparin therapy in a dose of 40 mg/day subcutaneously once positive pregnancy test is established and the therapy will continue until termination of pregnancy</description>
    <arm_group_label>Early Enoxaparin initiation</arm_group_label>
    <other_name>Clexan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>Women will start Enoxaparin therapy in a dose of 40 mg/day subcutaneously after sonographic confirmation of fetal cardiac pulsation and the therapy will continue until termination of pregnancy</description>
    <arm_group_label>Later Enoxaparin initiation</arm_group_label>
    <other_name>Clexan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women with APS diagnosed according to the revised classification criteria for
             APS in 2006 in Sydney, Australia

          -  Early pregnancy body weight is 50-90 Kg

        Exclusion Criteria:

          -  Women with systemic lupus erythematosus (SLE)

          -  Women with active thromboembolic disorders

          -  Women with history of previous thromboembolic disorders
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed I Eid, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed S Abdelhafez, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Waleed El-refaie, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmed El-Zayadi, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmed Badawy, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Obstetrics and Gynecology Department in Mansoura University Hospital</name>
      <address>
        <city>Mansourah</city>
        <state>Dakahlia</state>
        <zip>35111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private practice settings</name>
      <address>
        <city>Mansourah</city>
        <state>Dakahlia</state>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2014</study_first_submitted>
  <study_first_submitted_qc>December 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2014</study_first_posted>
  <last_update_submitted>November 27, 2017</last_update_submitted>
  <last_update_submitted_qc>November 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Mohamed Sayed Abdelhafez</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Antiphospholipid syndrome</keyword>
  <keyword>APS</keyword>
  <keyword>LMWH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Abortion, Spontaneous</mesh_term>
    <mesh_term>Antiphospholipid Syndrome</mesh_term>
    <mesh_term>Abortion, Habitual</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

